BIOTHERYX, INC.
Protein degrader therapeutics for cancer and inflammatory disease
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Latest Form D
- $92.1M, Jun 2021
- Total capital
- $93.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $93.8M
- 4 Form D · last Jun 2021
- 65 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 26
- 14 pending · first 2019
- Rank in peer group#49 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$92.1M
- Private capital raisedForm D · SEC · 3rd filing$500K
- Private capital raisedForm D · SEC · 2nd filing$150K
- Private capital raisedForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#49 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Christopher A. DevineDirectorNamed in SEC Form D filings
- David I. StirlingExecutive Officer, DirectorNamed in SEC Form D filings
- David Stirling, PhDExecutive Officer, DirectorNamed in SEC Form D filings
- Dung W.H. ThaiExecutive OfficerNamed in SEC Form D filings
- Frank W.H. MercurioExecutive OfficerNamed in SEC Form D filings
- Frank Mercurio, PhDExecutive OfficerNamed in SEC Form D filings
Show all 14 people
- Jack A. NoelkeDirectorNamed in SEC Form D filings
- Jaime A. DonadioExecutive OfficerNamed in SEC Form D filings
- Kyle W.H. ChanExecutive OfficerNamed in SEC Form D filings
- Kyle Chan, PhDExecutive OfficerNamed in SEC Form D filings
- Lawrence ZaslowExecutive Officer, DirectorNamed in SEC Form D filings
- Louis W.H. DeGennaroDirectorNamed in SEC Form D filings
- Louis DeGennaro, PhDDirectorNamed in SEC Form D filings
- Robert F. WilliamsonExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 26 granted of 40- GrantedIsoindolinones, Pharmaceutical Compositions, And Therapeutic ApplicationsUSPTOUS 12,662,467
- GrantedRas Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsUSPTOUS 12,630,547
- GrantedPDE4 Inhibitors, Pharmaceutical Compositions, And Therapeutic ApplicationsUSPTOUS 12,522,612
Show all 40 patent records
- Isoindolinones, Pharmaceutical Compositions, And Therapeutic ApplicationsJun 23, 2026 · US 12,662,467Granted
- Ras Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsMay 19, 2026 · US 12,630,547Granted
- PDE4 Inhibitors, Pharmaceutical Compositions, And Therapeutic ApplicationsJan 13, 2026 · US 12,522,612Granted
- Quinazolines, Pharmaceutical Compositions, And Therapeutic ApplicationsSep 23, 2025 · US 12,419,962Granted
- SOS1 Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsJun 12, 2025 · Application 18847237Pending
- Indazoles, Pharmaceutical Compositions, And Therapeutic ApplicationsNov 7, 2024 · Application 18626823Pending
- Estrogen Receptor Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsNov 7, 2024 · Application 18684902Pending
- Pyrazolylpyrimidines For Treating Malignant Solid TumorJun 27, 2024 · Application 18551926Pending
- SOS1 Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsJun 20, 2024 · Application 18550960Pending
- Kras Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsJun 13, 2024 · Application 18552482Pending
- Kras Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsJun 13, 2024 · Application 18542629Pending
- SOS1 Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsMay 30, 2024 · Application 18542628Pending
- PDE4 Degraders, Pharmaceutical Compositions, And Therapeutic ApplicationsApr 18, 2024 · Application 18256636Pending
- SOS1 Protein Degraders, Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsJan 25, 2024 · Application 18245125Pending
- Protein-targeting Compounds And Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsSep 22, 2022 · Application 17804566Pending
- Pharmaceutical Compositions Comprising One Or More Pyrone Compounds, And Their Use For Treating Inflammatory And Neurodegenerative DiseasesSep 6, 2022 · US 11,433,047Granted
- Aminoamide CompoundsAug 2, 2022 · US 11,400,084Granted
- Substituted IsoindolinonesJun 7, 2022 · US 11,352,338Granted
- Protein-targeting Compounds And Pharmaceutical Compositions Thereof, And Their Therapeutic ApplicationsMay 31, 2022 · US 11,345,712Granted
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofMay 31, 2022 · US 11,345,714Granted
- Bifunctional CompoundsMay 19, 2022 · Application 17649405Pending
- Fused Thiophene CompoundsMar 24, 2022 · Application 17457733Pending
- Bifunctional CompoundsFeb 1, 2022 · US 11,236,103Granted
- Bicyclic Compounds And Methods Of UseFeb 1, 2022 · US 11,236,105Granted
- Fused Thiophene CompoundsDec 7, 2021 · US 11,191,769Granted
- Ether Compounds And Uses ThereofFeb 23, 2021 · US 10,927,104Granted
- Aminoamide CompoundsFeb 2, 2021 · US 10,905,684Granted
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofJan 12, 2021 · US 10,889,593Granted
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofDec 8, 2020 · US 10,857,155Granted
- Substituted IsoindolinonesNov 24, 2020 · US 10,844,039Granted
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofJun 2, 2020 · US 10,669,260Granted
- Pyridinethiones, Pharmaceutical Compositions Thereof, And Their Therapeutic Use For Treating A Proliferative, Inflammatory, Neurodegenerative, Or Immune-mediated DiseaseMay 19, 2020 · US 10,654,805Granted
- Thienopyrimidinone CompoundsMar 10, 2020 · US 10,584,133Granted
- Bicyclic Compounds And Methods Of UseFeb 25, 2020 · US 10,570,147Granted
- Chimeric Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofFeb 18, 2020 · US 10,562,917Granted
- Ether Compounds And Uses ThereofDec 24, 2019 · US 10,513,515Granted
- Chimeric Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofSep 12, 2019 · Application 16153576Pending
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofSep 10, 2019 · US 10,406,165Granted
- Compounds Targeting Proteins, Compositions, Methods, And Uses ThereofJul 2, 2019 · US 10,336,771Granted
- Pyridinethiones, Pharmaceutical Compositions Thereof, And Their Therapeutic Use For Treating A Proliferative, Inflammatory, Neurodegenerative, Or Immune-mediated DiseaseMar 19, 2019 · US 10,233,153Granted
Related companies, and why
- HOLOCLARA, INC.Similar federal contract value in Biotech · null in contracts
- REVIVO THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- MetacrineSimilar federal contract value in Biotech · null in contracts
- Bedrock Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- COGENTIS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- VIROGENOMICS BIODEVELOPMENT, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .